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Supplementary Information  
 
 
An mGluR2 Agonist  
Recent studies show that heterodimers between 5-HT2A and a metabotropic 
glutamate receptor (mGluR), mGluR2, occur in cortical neurons, that they display 
unique functional interactions between the individual monomers, and that the contacts 
occur via transmembrane helices 4 and 5 of mGluR2 (1, 2).  The diacidic mGluR2/3 
agonist LY404039 shows promise in animal models for psychiatric disorders when given 
acutely (< 6 h before the test). A prodrug of this molecule has yielded partially promising 
clinical trials for schizophrenia over a 4-wk period (3, 4). It is not known whether 
LY404039 enters neurons or the endoplasmic reticulum (ER) via dicarboxylate carriers.  
If so, LY404039 would interact in the ER with mGluR2 or mGluR2-5HT2A receptors 
during the several weeks leading to clinically effective therapy; and although its 
pharmacokinetics differ markedly from those of the typical and atypical antipsychotic 
drugs, it would bind to its target in the early exocytotic pathway.   
 
Does Ketamine Block N-methyl-D-aspartate (NMDA) Receptors at the 
Concentrations Used for Depression? 
All investigators agree that ketamine exerts its ”rapid” antidepressant effects at 
“sub-anesthetic” concentrations; yet are these sufficient to block plasma membrane 
NMDA receptors? We comment on the concentrations of NMDA blockers required to 
exert the “rapid” antidepressant effect. A clinical trial showed effective antidepressant 
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activity for a bolus of 0.5 mg/kg (5); in mouse, the effective dose was 3 mg/kg (6).  
Pharmacokinetic measurements show that the half-life of ketamine in human and 
mouse brain is 186 and 13 min, respectively (7, 8), and suggest that, averaged over the 
first 30 min of action, the expected brain concentrations of ketamine are 100 and 300 
ng/ml respectively, corresponding to 0.4 to 1.2 μM. This would block less than half of 
NMDA receptors (9, 10).  We conclude tentatively that data are more consistent with the 
presence of another, tighter binding mode for the ketamine-NMDA receptor interaction; 
and throughout this essay we have argued that this additional mode could well occur in 
the ER. We note, however, that the details of “trapping block” at ligand-gated channels 
are modified by the binding and dissociation kinetics, by the fractional activation of the 
channel, by polyamine and glycine concentrations, and by the transmembrane voltage, 
leading to the possibility that ketamine does indeed block NMDA receptors completely 
at the clinically useful doses.  
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Table S1. Pharmacological chaperoning of G protein-coupled receptors by cell-
permeant ligands. 
Receptor 
Mutant / 
Wild-type Drug Reference
adenosine A1 mutant agonists; antagonists (11) 
dopamine D4 both transported dopamine; quinpirole; 
antagonists 
(12) 
gonadotropin-releasing 
hormone 
mutant antagonists (13) 
histamine H2 both agonist,     inverse agonist (14) 
opsin mutant -- (15) 
δ-opioid mutant antagonist (16) 
μ-opioid mutant agonists, antagonists (17) 
melanin concentrating 
hormone 
mutant antagonist (18) 
melanocortin-4 both antagonist, inverse agonist (19) 
vasopressin V1a both antagonist (20) 
vasopressin V1b/V3 both antagonist (21) 
vasopressin V2 both antagonists (22) 
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Figure S1. Most ideas about psychiatric therapeutics concentrate on (B), the late 
exocytotic / endocytotic pathway (henceforth called simply “late exocytotic pathway”).  
This review emphasizes (A), the early exocytotic / retrieval pathway (these are 
henceforth called simply the “late” “early exocytotic” pathways). G protein-coupled 
receptors (GPCRs), transporters, and ligand-gated channels are synthesized within the 
ER and glycosylated within the Golgi apparatus. Therapeutic targets, and the 
membranes that contain them, undergo budding, transport, reverse transport, and 
fusion trafficking in (A), in some ways analogous to the well-studied later steps in (B).  
SNARE proteins and vesicle budding participate in both pathways. In pathway (A), 
proteins leave the ER via either endoplasmic reticulum-associated degradation (ERAD) 
or via coated protein II complex (COPII) vesicles (23) (one shown enlarged at right, with 
its five major proteins (24)). The cargo (in this case a therapeutic target) binds directly to 
Sec24. COPII vesicles move from the ER to the ER-Golgi intermediate complex. COPI 
vesicles move from the Golgi to the ER. The components of ERAD, including the 
ubiquitin ligases, retrotranslocons, and proteasomes, are not shown. This review does 
not concern classical signal transduction by the receptors, which is thought to occur 
primarily at the plasma membrane via GPCRs and ligand-gated channels (but see (25)).  
Via the unfolded protein response, pathway (A) communicates directly with gene 
activation and protein synthesis (See figures in the main paper). 
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